Evommune Business Summary

Evommune, Inc. (EVMN) is a clinical-stage biotechnology company that generates revenue primarily through strategic licensing agreements and milestone-driven research collaborations, most notably its partnership with Maruho Co., Ltd. for the development of EVO756 in Japan. The company’s primary business segments focus on the discovery and clinical development of novel therapies for chronic inflammatory and immune-mediated diseases, specifically targeting atopic dermatitis (AD), chronic spontaneous urticaria (CSU), and ulcerative colitis. Evommune utilizes a proprietary tissue-based screening platform to advance a pipeline of small molecules and biologics, including its lead programs EVO756 (an MRGPRX2 antagonist) and EVO301 (an IL-18 inhibitor). Its direct competitors include Ventyx Biosciences, Spyre Therapeutics, and Vera Therapeutics; within this landscape, Evommune is positioned as a high-potential innovator following successful Phase 2a results for EVO301 and a $125 million private placement completed in February 2026. The company was co-founded by President and CEO Luis Peña and Chief Medical Officer Dr. Eugene Bauer, a duo with a proven track record including the co-founding of Dermira, which was acquired by Eli Lilly for $1.1 billion in 2020. The current executive leadership team includes CFO Kyle Carver, Chief Scientific Officer Dr. Jeegar Patel, and Chief Business and Legal Officer Gregory Moss, collectively offering deep expertise from previous roles at Genentech, Stiefel (GSK), and Theravance. Evommune is backed by a robust syndicate of institutional investors, including RA Capital Management, Sectoral Asset Management, and B Capital, with board representation from Derek DiRocco and François Beaubien. This seasoned executive team leverages decades of experience in dermatology and immunology to accelerate a pipeline that recently achieved critical proof-of-concept milestones in the global AD and CSU markets.